Answers are grounded in this paper and cite their sources.
Background Early identification of response to neoadjuvant therapy remains challenging in triple-negative breast cancer (TNBC), and conventional cell-density measurements may not fully capture treatment-induced changes in the spatial organisation of the tumour immune microenvironment. We investigated whether early spatial remodelling after a single treatment cycle was associated with subsequent pathological response. Methods This retrospective translational analysis used prospectively collected matched pre-treatment and post-cycle-1 core-needle biopsies from ten TNBC patients (five pCR and five non-pCR) enrolled in a clinical trial of neoadjuvant sintilimab, anlotinib and sequential chemotherapy. Six-colour multiplex immunofluorescence (CD8, CD20, CD68, FOXP3, PANCK and DAPI) was applied, and more than 1.7 million single cells were evaluated using a four-tier spatial framework comprising immune-cell density, tumour–immune spatial co-localisation, immune hotspot organisation and within-hotspot cellular interactions. Results After one treatment cycle, intratumoral and stromal CD8 + T-cell densities increased, whereas intratumoral CD68 + macrophages and stromal FOXP3 + regulatory T cells decreased. Tumour–CD20 + B-cell spatial co-localisation increased at the raw P-value level but did not survive FDR correction. The intratumoral immune hotspot score (Sintra/immune) decreased predominantly in patients who subsequently achieved pCR, and post-treatment values differed between pCR and non-pCR groups at the raw P-value level (P = 0.032; q = 0.064; exploratory ROC AUC = 0.92, 95% CI 0.66–1.00). Within immune hotspots, intratumoral CD68+–FOXP3 + interactions decreased and CD20+–CD8 + interactions increased across the cohort (both q < 0.05). Peritumoral CD20+–FOXP3 + interaction changes also differed between response groups (P = 0.032), although this association did not survive FDR correction. Conclusions These findings identify rapid spatial reorganisation of the TNBC immune microenvironment after a single treatment cycle and exploratory hotspot-level features associated with subsequent pathological response. Larger prospective cohorts are required for validation.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: